Ole Isacson
Corporate Officer/Principal chez Harvard Medical School
Fortune : 387 $ au 31/03/2024
Profil
Ole Isacson is currently the Director of the Neuroregeneration Institute at McLean Hospital, a Professor at Harvard Medical School, and a Member of the Harvard Stem Cell Institute.
He previously served as the Chief Scientific Officer and SVP of Neuroscience R&D at Pfizer Inc. and as the President of the Neural Transplantation and Repair division of the American Society for Neurological Therapeutics.
He was also the President of the International Cell division of the Transplantation Society.
Isacson holds undergraduate and doctorate degrees from the University of Lund.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2023 | 121 ( 0,00% ) | 387 $ | 31/03/2024 |
Postes actifs de Ole Isacson
| Sociétés | Poste | Début |
|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | 01/01/2002 |
McLean Hospital, Inc.
 McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services McLean Hospital, Inc. provides healthcare services. It offers specialized programs for the research and treatment of psychiatric and neurological illnesses, including: depression, bipolar and psychotic disorders, mood and anxiety disorders, substance abuse, geriatric mental illnesses and child adolescent psychiatric disorders. The company was founded in February, 1811 and is headquartered in Belmont, MA. | Corporate Officer/Principal | 01/01/2010 |
Harvard Stem Cell Institute
 Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Anciens postes connus de Ole Isacson
| Sociétés | Poste | Fin |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Director/Board Member | 19/11/2023 |
| PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01/05/2017 |
| Transplantation Society | Corporate Officer/Principal | - |
| American Society For Neurological Therapeutics | Corporate Officer/Principal | - |
Formation de Ole Isacson
| University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| CYCLERION THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Transplantation Society | |
McLean Hospital, Inc.
McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services McLean Hospital, Inc. provides healthcare services. It offers specialized programs for the research and treatment of psychiatric and neurological illnesses, including: depression, bipolar and psychotic disorders, mood and anxiety disorders, substance abuse, geriatric mental illnesses and child adolescent psychiatric disorders. The company was founded in February, 1811 and is headquartered in Belmont, MA. | Health Services |
Harvard Stem Cell Institute
Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Health Technology |
| American Society For Neurological Therapeutics |
